The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday.

Unlike BioNTech, Moderna's pipeline is nearly "all in" on mRNA assets. Most of them are infectious disease vaccines, particularly in COVID, flu, and RSV.

Moderna stock popped 11.7% to 47.53, while BioNTech shares 5.6% to 126.88. BioNTech stock is consolidating with a buy point at 131.49.

BioNTech SE BNTX and Moderna Inc MRNA are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic. Also Read: FDA Approves Updated ...

Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer treatment is one of the pharmaceutical industry’s biggest, most ...